Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient
Conclusion: Within the overall goal to establish operating procedures for breast cancer immunotherapy, we propose to re-evaluate testing for deficient mismatch repair and to further intensify the search for biomarkers predictive for the success of immune checkpoint modulation including all tumor biologic subtypes of breast cancer.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Gastroschisis Repair | Immunotherapy